Prospective Grant of Exclusive License: Use of Single Chain T-Cell Receptors To Diagnose and Treat Cancer, 19535 [E6-5531]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 72 / Friday, April 14, 2006 / Notices
pre- and post-natally, and for other
conditions.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: April 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–5530 Filed 4–13–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Single Chain T-Cell
Receptors To Diagnose and Treat
Cancer
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
wwhite on PROD1PC65 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in PCT Application Serial No.
PCT/US04/29608, filed September 13,
2004 [HHS Ref. No. E–106–2004/0–
PCT–01], entitled ‘‘Compositions
Comprising T-Cell Receptors and
Methods of Use Thereof,’’ to Altor
Bioscience Corporation, which is
located in Miramar, Florida. The patent
rights in these inventions have been
assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of single chain, soluble T-Cell Receptors
VerDate Aug<31>2005
16:37 Apr 13, 2006
Jkt 208001
19535
that recognize NY–ESO, MART–1, and
gp100 for diagnosis, prophylaxis, and
treatment of melanoma, myeloma,
sarcoma, head and neck cancer, bladder
cancer, esophageal cancer; lung cancer;
stomach cancer; breast cancer; ovarian
cancer, colorectal cancer, prostate
cancer or liver.
Dated: April 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–5531 Filed 4–13–06; 8:45 am]
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before June
13, 2006 will be considered.
DEPARTMENT OF HOMELAND
SECURITY
Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Michelle A. Booden,
PhD., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 451–
7337; Facsimile: (301) 402–0220; E-mail:
boodenm@mail.nih.gov.
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
DATES:
ADDRESSES:
The
technology describes the composition
and use of nucleic acid sequences that
encode polypeptides capable of forming
a T-Cell Receptor (TCR) in a genetically
engineered cell. Specifically, these
nucleic acid sequences will encode
TCRs specific to tumor associated
antigens (TAA), gp100, NY–ESO–1, and
MART–1. T-Cells engineered with these
tumor associated antigen specific TCRs
show specific immune responses against
TAA expressing cancer cells.
Additionally, a method of treating or
preventing cancer by administrating the
above described TCRs is also disclosed.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
Federal Emergency Management
Agency
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: Notice and request for
comments.
AGENCY:
SUMMARY: The Federal Emergency
Management Agency (FEMA) has
submitted the following information
collection to the Office of Management
and Budget (OMB) for review and
clearance in accordance with the
requirements of the Paperwork
Reduction Act of 1995. The submission
describes the nature of the information
collection, the categories of
respondents, the estimated burden (i.e.,
the time, effort and resources used by
respondents to respond) and cost, and
includes the actual data collection
instruments FEMA will use.
Title: Application for Community
Disaster Loan Program (CDL)/Special
Community Disaster Loan Program
(SCDL).
OMB Number: 1660–0083.
Abstract: The Application for
Community Disaster Loan (CDL)
Program and the Special Community
Disaster Loan Program (SCDL) provide
States, Local and Tribal governments
that have suffered substantial loss of tax
or other revenues as a result of a major
disaster or emergency, the opportunity
to obtain financial assistance in order to
perform their governmental functions.
Affected Public: State, local, or tribal
government.
Number of Respondents: 103.
Estimated Time per Respondent:
Burden for this collection is 15.2 hours
for the Traditional CDL and 13.4 hours
for the Special CDL.
Estimated Total Annual Burden
Hours: 1,812.
Frequency of Response: Once.
Comments: Interested persons are
invited to submit written comments on
the proposed information collection to
the Office of Information and Regulatory
E:\FR\FM\14APN1.SGM
14APN1
]]>Agencies
[Federal Register Volume 71, Number 72 (Friday, April 14, 2006)]
[Notices]
[Page 19535]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-5531]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Single Chain T-
Cell Receptors To Diagnose and Treat Cancer
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of an exclusive patent license to practice the inventions
embodied in PCT Application Serial No. PCT/US04/29608, filed September
13, 2004 [HHS Ref. No. E-106-2004/0-PCT-01], entitled ``Compositions
Comprising T-Cell Receptors and Methods of Use Thereof,'' to Altor
Bioscience Corporation, which is located in Miramar, Florida. The
patent rights in these inventions have been assigned to the United
States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of single chain, soluble T-
Cell Receptors that recognize NY-ESO, MART-1, and gp100 for diagnosis,
prophylaxis, and treatment of melanoma, myeloma, sarcoma, head and neck
cancer, bladder cancer, esophageal cancer; lung cancer; stomach cancer;
breast cancer; ovarian cancer, colorectal cancer, prostate cancer or
liver.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before June
13, 2006 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, PhD., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; E-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology describes the composition and
use of nucleic acid sequences that encode polypeptides capable of
forming a T-Cell Receptor (TCR) in a genetically engineered cell.
Specifically, these nucleic acid sequences will encode TCRs specific to
tumor associated antigens (TAA), gp100, NY-ESO-1, and MART-1. T-Cells
engineered with these tumor associated antigen specific TCRs show
specific immune responses against TAA expressing cancer cells.
Additionally, a method of treating or preventing cancer by
administrating the above described TCRs is also disclosed.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: April 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-5531 Filed 4-13-06; 8:45 am]
BILLING CODE 4140-01-P
